To include your compound in the COVID-19 Resource Center, submit it here.

Genmab, Seattle Genetics to start Phase II of tisotumab vedotin in cervical cancer

Genmab A/S (CSE:GEN; Pink:GMXAY) and Seattle Genetics Inc. (NASDAQ:SGEN) plan to begin a single-arm

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE